28.11.2022 • News

TotalEnergies to Build Recycling Unit for PP

France’s TotalEnergies said it plans to build a new production line for high-performance recycled polypropylene used in automotive applications at its polymer production site in Carling, France.

Since 2016, the Saint-Avold petrochemical platform has produced high-end value-added compounds for the automotive industry. The new line earmarked for start-up in 2024 will have capacity for 15,000 t/y of polypropylene compounds containing up to 100% recycled plastic materials.

The output will be part of TotalEnergies’ recently launched new RE:clic low-carbon polymer portfolio, which is based on recycled material and bio-feedstocks. The materials of its related RE:use polymer range obtained through a mechanical recycling process meet the highest quality standards and technical requirements of the automotive industry, the French company said.

© OceanProd/ liscence free
© OceanProd/ liscence free

After doubling the capacity at subsidiary Synova, which it claims is “the French leader in the production of recycled polypropylene,” Total said the new investment further strengthens its leading position in high value-added recycled polymers.

With the ability to recycle both post-consumer waste and end-of-life automotive parts, the company said the new line will help address the challenge of the circular economy in Europe. Total’s goal is to increase the share of circular polymers in its portfolio to 30% by 2030.

Author: Dede Williams, Freelance Journalist

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read